[Frontiers in Bioscience 5, d367-371, March 1, 2000]

HOME
Current Issue
VITAL LINKS
INDEX
Full Text
PDF FILE
ACCESS PUBMED
REPRINTS
CAVEAT LECTOR

Send correspondence to:

Andrew Arnold, M.D.,
Center for Molecular Medicine,
University of Connecticut Health Center,
263 Farmington Avenue,
Farmington, CT 06030-3101

Tel:860-679-7640,
Fax: 860-679-7639,
E-mail: AArnold@nso2.uchc.edu3

KEY WORDS

Parathyroid, Adenoma, Cyclins, Neoplasms, Cancer, Tumor, Growth, Proliferation, Review

SEARCH FBS

Copyright © Frontiers in Bioscience, 1995

CYCLIN D1 IN PARATHYROID DISEASE

Sanjay M. Mallya and Andrew Arnold

Center for Molecular Medicine, University of Connecticut Health Center, Farmington, CT. USA

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Cloning of the PRAD1/Cyclin D1 oncogene
4. Cyclin D1 in parathyroid tumorigenesis
5. Future Directions
6. References

1. ABSTRACT

Primary hyperparathyroidism (HPT), most commonly due to parathyroid adenoma, is a disorder characterized by excessive secretion of PTH. So far, abnormalities in two genes, cyclin D1 and MEN1, have been implicated in the development of parathyroid adenomas. Cyclin D1, now an established Oncogene involved in numerous human cancers, was first identified and recognized as an Oncogene in the study of parathyroid tumors. A subset of parathyroid adenomas contains a clonal rearrangement that places the PTH gene's regulatory sequences in proximity to the cyclin D1 Oncogene causing its overexpression, and 20-40% of parathyroid adenomas overexpress the cyclin D1 protein. Transgenic animal models have further confirmed the role of cyclin D1 as a driver of abnormal parathyroid cell proliferation. Future studies on the mechanism of cyclin D1's oncogenicity and its interactions with other parathyroid growth regulators will further our understanding of parathyroid cell biology and may prove useful clinically.